Mode
Text Size
Log in / Sign up

FDA approved Rezenopy (naloxone) for Emergency Treatment of Opioid OverdoseFDA approved new nasal spray called Rezenopy for emergency treatment of opioid overdose

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider Rezenopy for emergency opioid overdose reversal with intranasal dosing and immediate medical follow-up.

The FDA approved Rezenopy (naloxone) nasal spray on April 19, 2024, for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. This approval provides a new intranasal formulation of naloxone hydrochloride, intended for immediate administration as emergency therapy in settings where opioids may be present, such as community or home use by non-healthcare providers. Rezenopy is not a substitute for emergency medical care, and patients or caregivers must seek immediate medical assistance after use, highlighting its role in bridging critical time until professional help arrives. The drug's approval addresses the ongoing opioid crisis by offering a user-friendly option for rapid reversal of overdose effects, though clinical trial data specifics are not detailed in the label, emphasizing reliance on established naloxone pharmacology.

Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Mechanism of Action

Not reported in label.

Indication & Patient Population

Rezenopy nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.

Dosing & Administration

Rezenopy nasal spray is for intranasal use only. The recommended initial dose in adults and pediatric patients is one spray delivered intranasally into one nostril. If the patient does not respond within 2 to 3 minutes or responds and then relapses into respiratory depression, an additional dose may be given into the other nostril with a new device. Repeat doses every 2 to 3 minutes as needed, alternating nostrils and using a new device each time, until emergency medical assistance arrives. Important instructions include: seek emergency medical care immediately after use, do not prime or test the device prior to administration, place the patient in supine position, support the back of the neck and tilt the head back, and turn patient on their side after administration. For partial agonists or mixed agonist/antagonists like buprenorphine, reversal may be incomplete and require higher doses or repeat administration.

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

Not reported in label.

Place in Therapy

Rezenopy nasal spray is an opioid antagonist for emergency treatment of opioid overdose, intended for use by non-patients in community settings. It requires immediate medical follow-up and may need repeat dosing due to opioid duration exceeding naloxone's effect. Additional supportive measures are recommended while awaiting emergency assistance.

The U.S. Food and Drug Administration has approved a new medication called Rezenopy, which is a nasal spray form of naloxone. This drug is specifically for emergency treatment of opioid overdose when someone shows signs like slow breathing or being unresponsive. It works by quickly reversing the effects of opioids in the body, which can help save lives during an overdose emergency.

Rezenopy is approved for both adults and children who may be experiencing an opioid overdose. It's designed to be easy to use by people who aren't healthcare professionals, making it suitable for home or community settings where opioids might be present. The approval reflects ongoing efforts to address the opioid crisis by providing more accessible treatment options.

This approval means there's now another formulation of naloxone available that can be administered as a nasal spray rather than an injection. Having different options available can help ensure that more people have access to this life-saving medication when they need it most.

It's important to remember that Rezenopy is not a substitute for emergency medical care. Anyone who uses this medication should still call for emergency help immediately after administering it. As with any medication, patients should talk with their doctor about whether this might be appropriate for their situation and how to use it properly.

What this means for you:
New nasal spray can reverse opioid overdose effects, but you still need to call emergency services immediately.

Study Details

Study typeFda approval
PublishedApr 2024
View Original Abstract ↓
1 INDICATIONS AND USAGE REZENOPY nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. REZENOPY nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. REZENOPY nasal spray is not a substitute for emergency medical care. REZENOPY nasal spray is an opioid antagonist for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ( 1 ) REZENOPY nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) REZENOPY nasal spray is not a substitute for emergency medical care. ( 1 )
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.